旭輝控股集團(00884.HK):購回並註銷460萬美元優先票據
格隆匯12月30日丨旭輝控股集團(00884.HK)公佈,有關於2022年1月到期的5.5%優先票據。於2021年11月4日至2021年12月17日,公司已購回本金總額為460萬美元的該等票據,相當於原定發行該等票據的本金總額0.79%。購回票據已根據該等票據的條款及條件予以註銷。截至公吿日期,本金總額為7990萬美元的該等票據已獲購回及予以註銷,相當於原定發行該等票據的本金總額約13.66%。
截至公吿日期,該等票據的尚未償還本金總額為5.051億美元,相當於原定發行該等票據的本金總額約86.34%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.